Repligen (RGEN) Q4 2019 Earnings Call Transcript

Repligen (RGEN 0.22%)
Q4 2019 Earnings Call
Feb 20, 2020, 8:30 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Good day, ladies and gentlemen, and welcome to the Repligen Corporation's year-end and fourth quarter of 2019 earnings conference call. My name is Rocco, and I will be your coordinator. [Operator instructions] Please note, today's event is being recorded. I would now like to turn the call over to your host for today's call, Sondra Newman, global head of investor relations for Repligen.

Please go ahead.

Sondra Newman -- Global Head of Investor Relations

Great. Good morning, everyone. Thanks for joining our call today. On this call, we'll cover our financial results and business highlights for Repligen's fourth fiscal-quarter and full-year 2019, and we'll provide financial guidance for the year 2020.

Our president and CEO, Tony Hunt will cover business updates; and our, CFO Jon Snodgres will cover our financial results and guidance. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for financial performance of the company are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risk factors is included in our annual report on Form 10-K, the current report on Form 8-K, which we filed today and other filings that we make with the Securities and Exchange Commission. Today's comments reflect our current views, which could change as a result of new information, future events or otherwise.

And the company does not obligate or commit itself to update forward-looking statements, except as required by law. During this call, we are providing non-GAAP results and guidance. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen's website and on sec.gov. The non-GAAP figures in today's report include revenue growth at constant currency, gross profit and gross margin, operating expenses, including R&D and SG&A, operating income and operating margin, income tax expense, net income and earnings per share, as well as EBITDA and adjusted EBITDA.

These adjusted financial measures should not be viewed as an alternative to GAAP measures, but are intended to better enable investors to benchmark Repligen's current results against historical performance and the performance of peers. Now I'll turn the call over to Tony Hunt.

Tony Hunt -- President and Chief Executive Officer

Thank you, Sondra. Good morning, everyone, and welcome to our 2019 year-end update. We are delighted with the way we finished off the year with 21% organic growth in the fourth quarter, 33% organic growth for the full-year and overall 2019 growth for the company, coming in at 39%. All three franchises accelerated in 2019 as we benefited from customers scaling up on mAb processes and new customers implementing our technologies, especially in the area of gene therapy, where we now have greater than 50 significant customers today and just as many smaller customers.

Throughout the year, our team continued to execute on our long-term growth strategy with M&A and R&D remaining at the core of our success. In 2019, we completed our acquisition of C Technologies, establishing an important new vertical for the company in process analytics. Our R&D team delivered TFDF filtration technology, a game-changing technology and harvest clarification, an area that has seen little innovation over the last 10 to 20 years. Supporting our growth strategy and operational investments in 2019, we completed a series of financings that leave us with over $500 million in cash at year-end and positions us well for the future.

Looking back at the year, there were five key drivers of growth. First, as I mentioned, we saw strong adoption of gene therapy accounts where we help to deliver yield and efficiency improvements in viral vector manufacturing. Gene therapy represented approximately 15% of our overall 2019 revenue with filtration products accounting for 60% and chromatography products accounting for 35% of sales into these accounts. We saw a fairly even split between CDMO and gene therapy developers at 52% and 48% of revenue, respectively.

And with the strong base of core customers and differentiated technology, we are really well-positioned for growth in gene therapy. Second, we saw increased adoption of our XCell ATF products in both N-1 seed train, a traditional perfusion applications. The expansion of ATF applications into fed-batch processes is a key growth driver for us as it is the catalyst for sustained long-term growth north of 20%. Third, we saw significant uptick of our TFF systems portfolio where we put more focus on tying systems and consumables into targeted upstream and downstream applications.

We made the decision 12 months ago to focus on building out systems for our TFF portfolio. And not only has this team delivered on more traditional UF/DF applications, but they've also delivered on the development and launch of TFDF technology and fed-batch harvest clarification. Fourth, we saw accelerated adoption of our OPUS prepacked columns as CDMOs and pharma customers continue to scale and expand. Combined with new demand for OPUS and gene therapy, we delivered approximately 1,400 comps to our customer base in 2019, up from 700 comps in 2018.

To ensure our ability to stay ahead of demand, we made significant investments in 2019 and here again in 2020 to expand our capacity and resources at OPUS production. And finally, just the overall strength of the biologics market, where in the U.S. alone, 10 new mAbs and two gene therapy drugs were approved in 2019. With a rich pipeline of over 1,000 biological drug candidates, the expectations are high for strong growth in the years ahead.

Before jumping into the quarter, I also wanted to highlight some of our key accomplishments in 2019. Starting with C Technologies, which was our first acquisition in process analytics. During our seven months of C Tech ownership in 2019, we focused our efforts on commercial expansion, R&D acceleration and building out the financial team and implementing public company processes at C Tech. We successfully built our commercial team with 10 dedicated reps, we focused R&D efforts on accelerating next-gen FlowVPE, and we completed the build-out of the finance team.

For the year, C Tech products contributed close to $16.4 million in revenue, right in line with our $16 million to $17 million projection. We look forward to seeing the impact of our new commercial team in 2020, where we expect C Technologies to generate approximately $32 million in revenue. Moving now to R&D. 2019 was a year where we made significant progress.

A key goal for us entering the year was to develop and launch TFDF technology. We did a very successful technical launch of the product in September, and then our systems team followed up with the development of benched-up and production scale systems, which will be launched here in Q1. We also made progress with our next-gen ATF controller, which is scheduled to launch in late Q1, early Q2. In addition, key products like CS gamma and next-gen ligands are reaching their final stages of product development and will soon be available in the marketplace.

From a capacity and infrastructure standpoint, 2019 was a huge year for us. We increased our office capacity fivefold and have dedicated programs in place to expand again in 2020. Our operations team also expanded and centralized manufacturing of XCell ATF in Marlborough and completed the Phase 1 implementation of SAP. Financially, we were able to raise close to $500 million net through a series of equity and convertible debt financings, again, putting us in a strong position for future M&A.

So moving now to our Q4 results and full-year 2019 performance. As reported today, we had a great quarter with $69.5 million in sales. The story of the quarter was our organic growth performance against difficult comps. Each of our proteins, filtration and chromatography franchises performed well and together delivered 20% plus organic growth in the quarter and 20%, 30% and 40% organic growth, respectively, for the year.

In filtration, our XCell ATF product line had a record year. Our customers scaled up into late stage trials, and we saw increased use of ATF and N-1 seed train applications, reflecting a broader application of the technology into fed-batch processes. Single-use ATF continued to perform well in 2019, with revenue growth of 45%. Our CS flat sheet TFF cassette business also had a very strong quarter and year, up over 25%.

The story continues to be around new accounts and key wins in gene therapy applications. Our hollow fiber portfolio also had a good quarter in Europe, 30% with the robust demand for single-use flow paths, hollow fiber modules and KrosFlo systems. We expect that our hollow fiber business will have another strong year in 2020. And our overall filtration franchise will grow approximately 25%.

Moving to chromatography for our OPUS business finished up over 30% for the quarter and 50% for the year. The story in the quarter was the continued adoption of our prepacked column technology in CDMOs and gene therapy accounts, which now account for 20% of our OPUS revenue. In parallel, we were able to improve our lead times significantly by bringing 5 new production suites online in December. We also saw accelerating adoption to focus ATF columns, as customers put our technology into late-stage and commercial processes.

We expect continued momentum for OPUS in 2020 as our customers scale and expand. We expect our OPUS franchise to grow at or above 20% in overall chromatography at 15% in 2020. Our OEM proteins business performed well in Q4 and was up 20% for the full year, led by strengthened growth factors with 50% growth from ligands. As mentioned, throughout 2019, we expect GE to transition to in-house ligand manufacturing here in 2020, creating a $12 million to $13 million or 4% to 5% headwind for the company.

We expect that NGL-Impact A ligand will continue to gain traction in the marketplace as customers implement this technology in early stage clinical trials. So overall, we expect the company to grow at 14% to 18% in 2020, with organic growth in the 10% to 14% range. We expect H2 to be stronger than H1 as some of the larger scale-up projects is in the second half of 2020. Unlike other companies, it will take a few more months to understand what the long-term impact might be on overall company performance from the coronavirus in China in fiscal-year 2020.

For quarter one, there may be some shift in revenue into Q2 based on customer timing. As we move into 2020, our strategic priorities will center on the following: new product launches with a focus on TFDF and ATF controllers, expanding our market presence in harvest clarification applications with TFDF technology, further expanding our market presence in gene therapy through our filtration and chromatography franchises; broadening the customer base and applications for C Technologies; implementing capacity expansion and operating margin improvement programs; and finally, evaluating M&A opportunities to supplement our organic growth. In summary, we believe we are well-positioned to gain further share by processing. We believe that the blueprint we've put in place over the last five years around building out a world-class commercial team, bringing disruptive technologies to market and supplementing our technology base with select M&As will be the catalyst for growth over the coming years.

Also, based on the investments we've made in R&D over the last three years, we expect 2020 to be a milestone year for us in terms of product launches. Before concluding, I wish to recognize our employees around the globe for their commitment and leadership in 2019. I also want to thank our loyal shareholders and customers for their parts in Repligen's success and we look forward to another strong year for the company and bioprocessing. With that, I'll turn the call over to Jon for a more detailed financial report.

Jon Snodgres -- Chief Financial Officer

Thank you, Tony, and good morning, everyone. Today, we are reporting our financial results for the fourth-quarter and full-year 2019, as well as providing our financial guidance for the year 2020. Unless otherwise mentioned, all financial measures discussed reflect non-GAAP measures. As you've seen in our press release this morning, we delivered strong financial performance for both the fourth-quarter and full-year 2019.

We had another strong quarter with revenues of $69.5 million, representing 34% reported growth and 21% organic growth. For full-year 2019, we reported record revenue of $270.2 million. The year-over-year increase of $76 million represents 39% overall growth, including 2 points of foreign currency headwind and 33% organic growth, $16 million or 8% of our revenue growth was attributed to our June 2019 acquisition of C Technologies. Operationally, we continue to prioritize key areas of investments in the company.

In 2019, 7% of revenue supported R&D programs that continue to produce disruptive technologies, like our new TFDF platform that we launched in the second half of the year. We also made important capital investments in our manufacturing sites, with a significant portion of our spend dedicated to increasing overall production capacity and expanding and upgrading our IT systems and infrastructure. Now to provide more insights into our overall financial performance. As Tony mentioned earlier, our direct-to-customer franchises continue to perform well.

Our direct products represented 79% of the company's total revenue in the fourth quarter and 76% for the full year, compared to 72% for full-year 2018. On a regional basis, for the full year, pro forma direct product revenue growth was fairly consistent across regions, with approximately 30% growth in North America, Europe and Asia. For the full-year 2019, Asia represented 16% of direct revenue, while Europe and North America accounted for 28% and 56%, respectively. Now moving to our income statement.

Fourth-quarter adjusted gross profit was $39.8 million, representing an increase of $11.3 million or 40% over the fourth quarter of 2018. Our adjusted gross margin was 57.2% for the fourth quarter of 2019, compared to 54.8% for the same period in 2018. The 240-basis-point improvement was driven by favorable OPUS column to resin mix in our chromatography franchise and by increased demand for growth factor products in our proteins franchise. Full-year 2019 adjusted gross profit of $154.1 million reflects an increase of $45.9 million or 42% compared to the full year of 2018.

Adjusted gross margin was 57% for the full-year 2019, compared to 55.8% for 2018, with the 120-basis-point increase, driven by overall sales volume leverage in our factories, our new C Technologies product line and favorable product mix, partially offset by investments in capacity and operations. With respect to operating expenses. Adjusted research and development costs for the fourth quarter of 2019 were $4.9 million, compared to $3 million for the fourth quarter of 2018. For the full-year 2019, adjusted R&D expenses were $18.8 million, compared to $15.7 million in 2018.

Key drivers of the year-over-year increase were the timing of our C Technologies acquisition, investments in our next-generation filtration technologies, as well as continued investments in our ligand programs. Overall, R&D expenses finished the year at 7% of revenue. Adjusted SG&A for the fourth quarter of 2019 was $22.2 million, compared to $14.4 million for the fourth quarter of 2018. Full-year adjusted SG&A was $71.8 million in 2019, compared to $53.1 million in 2018.

The year-over-year increase in adjusted SG&A was related to the timing of our C Technologies acquisition and the build-out of our process analytics commercial team, as well as expansions and enhancements of our facilities, IT systems and commercial team. Now moving to adjusted earnings and EPS. In the fourth quarter of 2019, our adjusted operating income was $12.7 million, a 15% increase, compared to $11.1 million reported in the fourth quarter of 2018. Our adjusted operating margin was 18.3%, compared to 21.3% for the fourth quarter of 2018.

Our operating costs during the fourth quarter of 2019 included approximately $1 million of nonrecurring expenses, mostly in IT and recruiting. For the full year of 2019, our adjusted operating income was $63.5 million, a 61% increase, compared to $39.4 million for the full year of 2018. Our 2019 full-year adjusted operating margin was 23.5%, a 320-basis-point improvement, compared to 20.3% for the 2018 period, reflecting a strong year of growth and operational execution in our business. Adjusted net income for the fourth quarter of 2019 was $10.8 million, an increase of 21%, compared to $8.9 million in the same period in 2018.

Full-year 2019 adjusted net income was $52.5 million, an increase of 74%, compared to $30.1 million for the full-year 2018. Adjusted EPS for the fourth quarter of 2019 increased to $0.20 per fully diluted share from $0.19 for the fourth quarter of 2018. For the full year of 2019, adjusted EPS increased to $1.07, up 62% from $0.66 in 2018. Our cash and cash equivalents, which are GAAP metrics, totaled $528.4 million at December 31, 2019.

For full-year 2019, we generated free cash flow of $44.1 million, inclusive of $67.2 million of operating cash flow, less $23.2 million of capital investments primarily related to our facility and capacity expansion projects and IT systems investments. Now moving to 2020 full-year guidance. Our GAAP to non-GAAP reconciliations for our 2020 financial guidance are included in the reconciliation tables in today's earnings press release. As previously mentioned, unless otherwise noted, all 2020 financial guidance discussed will be non-GAAP.

Please also keep in mind that our 2020 guidance may be impacted by fluctuations in foreign exchange rates beyond our current projection of a net zero impact on full-year sales and does not include the potential impact of any new acquisitions that the company may pursue. Today, we are setting our 2020 full-year revenue guidance, a GAAP metric at $309 million to $319 million, reflecting growth in the range of 14% to 18% as reported and 10% to 14% on an organic basis. Our adjusted gross margin guidance for 2020 is 55% to 56%, which reflects the impacts of expected headwinds from lighter GE volumes and investments in our facilities, capacity, IT systems and staffing to support expected strength and long-term market demand and overall growth. Adjusted operating income is expected to be in the range of $70 million to $74 million, with adjusted operating margins in the range of 22% to 23% of revenue for the year.

We are expecting 2020 adjusted income tax expense of approximately 23% of adjusted pre-tax income, which anticipates impacts from strong international revenue growth in higher tax rate countries in Europe and Asia. We are expecting full-year 2020 adjusted net income in the range of $57 million to $60 million for the year, and adjusted EPS in the range of $1.07 to $1.12 per fully diluted share. Please note that our 2020 adjusted EPS guidance reflects a $0.09 dilution impact due to share count increases, primarily related to our 2019 financing activities. Our guidance reflects an estimated 53.4 million fully diluted shares outstanding for the full year, an increase of approximately 4 million.

Adjusted EBITDA is now expected to be in the range of $80 million to $84 million for the full-year 2020, with depreciation and intangible amortization expense is expected to be approximately $10.5 million and $15.5 million, respectively. The company again expects to invest an estimated $20 million to $22 million in 2020 for capital expenditures as we proceed with our build-out of our OPUS manufacturing facility in Breda, planned capacity expansions in our Massachusetts and California facilities and with continued investments in SAP. We expect 2020 year-end cash and cash equivalents, a GAAP metric to be in the range of $580 million to $590 million, with our capex investments being fully funded by cash generation from our operations. As you can see, we've executed on another strong year of performance in 2019, including making substantial investments in the company as part of our two-year plan to prepare us for continued long-term growth.

This completes our financial report, and I will now turn the call back to the operator to open the lines for questions.

Questions & Answers:

Operator

Thank you. [Operator instructions] Today's first question comes from Dan Arias of Stifel. Please go ahead.

Dan Arias -- Stifel Financial Corp. -- Analyst

Thanks, guys. Maybe just to start on guidance. 32% organic is a pretty big year. So obviously, you have a tough comp there.

When you look at the momentum that you're exiting 2019 with though, can you just talk about the approach to the 2020 outlook in terms of being conservative or not conservative? And then how you feel about just the shape of the business and the drivers that you have relative to this time last year when you guided to, I believe, 13% to 17% organic growth. So less than half of what you ended up doing?

Tony Hunt -- President and Chief Executive Officer

Yeah. Thanks, Dan. Yeah, I think in general, we finished off the year. We had good momentum through the second half of the year.

I think as we looked at 2020 guidance, I think it was important for us to really gauge what was going on in each of the businesses, right, in each of the divisions. So within chromatography and filtration, we feel pretty good about it. Our OPUS business came off a massive year last year, up over 50%. And our filtration product line also had a really, really big year.

So we've got really difficult comps in 2020. We expect that our filtration franchise will grow 25%. We think that our OPUS franchise will grow 20% plus. Our proteins business is probably the main headwind that we have and so we know we have a 4% to 5% headwind going into 2020.

So if you take our 10% to 14% guidance. And we didn't have that headwind, we would really be doing 15% to 19%. So we think, actually, the guidance we're putting out there right now is very realistic. While we feel really good about our businesses, really good about our products, we think this is the right guidance for us.

To your second part of your question about last year where we guided mid-teens, and we came in at 30%. I think the piece that really surprised us last year was the proteins business, right? And we had guided down 5%, and it came in really, really strong. So if you take that out of the equation, it would really drop down the overall organic growth pretty significantly. So I think that was a big factor.

I think the other factor last year is that no one really in the industry predicted how fast the gene therapy market was going to grow. And I think we all kind of missed that a little bit. And so that's kind of the explanation for last year.

Dan Arias -- Stifel Financial Corp. -- Analyst

Yeah. OK. That's actually my second question. Just on gene therapy, is there some color you can give on just how you feel about the expansion and the evolution of that market in terms of new activity and the scale of our project work.

And then I guess, along those lines, I mean, one of the things that it sounded like you were trying to stay grounded on last year was this idea that a lot of things went right in 2019 in that field. And that that always doesn't happen, Phase 1 don't always go to Phase 2, etc. So I guess the question is that sitting two months into the new year, how are you looking at things relative to the way that you would have hoped they would have been six to 12 months ago?

Tony Hunt -- President and Chief Executive Officer

Yeah. I think when you look at how we finished in Q4, the gene therapy customer base was again strong for us in terms of shipments, in terms of orders as it's difficult for us to see much beyond the first half of the year. We know, as I said earlier in my prepared remarks that we know there are some significant scale-up programs that are happening in the second half of the year. But in general, we haven't seen any slowdown in gene therapy, and we're expecting gene therapy will grow about 30% for us in 2020.

Dan Arias -- Stifel Financial Corp. -- Analyst

OK. It sounds like you've given the three questions here, so I'll take the opportunity. Maybe just on TFDF, that sounds like it's one of the more meaningful products in the portfolio these days. So what is the thought on just the industry coming around to the dual filtration benefit that you get there.

My sense is that that might take a year or two for that to ramp and be a material contributor. Is that the way that you're thinking about it? And then what does the runway look like if you wanted to look beyond just this year and into 2021 and 2022?

Tony Hunt -- President and Chief Executive Officer

Yeah, I think you have it spot on. It's going to take a couple of years for TFDF to take off, but we've got a significant number of trials lined up here in Q1. We expect it will generate $1 million, $2 million in revenue for us this year. But every year, going forward, we expect that revenue will double.

And so it's not one of those product lines that we expect to grow at 20%, 25%, 30%. We expect that over the next few years, this is a technology that's going to scale quickly. But obviously, we've to get through the trials, we've got approved the technology. We've done that so far, but on a limited basis, and I think we're very confident that the technology is going to be a key technology for us.

That said, I wouldn't underestimate the rest of the product launches that we're bringing to market this year. So we really are bringing innovation in ATF. We're bringing out the next-generation FlowVPE technology in the second half of the year. We've got new ligands coming through.

We've got next-generation, CS gamma. Really feel this year is a key year for us in terms of product launches that will set us up really well for 2021 and beyond.

Dan Arias -- Stifel Financial Corp. -- Analyst

Understood. OK. Thanks, Tony.

Tony Hunt -- President and Chief Executive Officer

Yeah. Thanks, Dan.

Operator

And our next question today comes from Puneet Souda of SVB Leerink. Please go ahead.

Puneet Souda -- SVB Leerink -- Analyst

Yeah, hi, Tony. Thanks for the question. So first one on, if I could touch on C Tech in terms of your expectation of that product after the increase in the sales force. When we look at the number you provided for 2020 in light of sort of the growth that you're already seeing in the business, and what you're going to see and the second-half acceleration? Just help us understand why is that number for 2020 C Tech a little bit conservative than sort of given the efforts of sales force behind it? And when can we realistically see acceleration in that piece of the business?

Tony Hunt -- President and Chief Executive Officer

Yeah So C Tech, just to maybe take a step back, so when we did the acquisition, we really felt that the second half of the year or the seven months of ownership, we would be somewhere between $16 million and $17 million, and we came in at $16.4 million. Long conversations with Craig and the team down in Bridgewater, and it was pretty clear that as we did the deal that they were at that inflection point where one salesperson and distributors around the world was just not going to be able to drive the growth that they had seen in prior years. So they had a fairly slow first half of the year. So the $32 million projection for us in 2020 is 25% growth.

So I think that's a really meaningful growth number for C Tech. Now I'm totally thrilled that we've been able to get nine additional salespeople on board by the end of 2019. They're all getting up and running, and we expect second half of the year that C Tech will be stronger than the first half of the year in terms of revenue. And I think when we get later in the year, we'll have a much better sense of in 2021 and 2022, how fast can this technology or product line grow, but we expect it's definitely a 20% plus grower going forward.

And it just really comes down now to not only how fast we can accelerate adoption of SoloVPE outside North America, which is predominantly where the technology is being sold over the last few years to also the rapid deployment of the next-generation version of FlowVPE, which we are really bullish on, and we think that's got a lot of potential, especially in the out years.

Puneet Souda -- SVB Leerink -- Analyst

OK. Thanks. And then on China, if I could ask, I appreciate your comments on first quarter. But I was wondering what's your supply chain exposure in China? And what's your expectation there for the next couple of quarters? How that changes?

Tony Hunt -- President and Chief Executive Officer

Yeah. On the supply chain side, it's pretty minimal for us. We don't have a lot of products that are coming into our supply chain that's made in China. So there are some, but it's small in the grand scheme of things.

So obviously, we continue to manage that. On the revenue side, it's really just dealing with potential shift as we finish on Q1 and go into Q2. And in general, our exposure in China is about 5% of our revenue, which, if you just average it out over four quarters, it's about $4 million a quarter.

Puneet Souda -- SVB Leerink -- Analyst

OK. And then last one, if I could ask on gene therapy. Obviously, a strong business for you. You mentioned 15% overall mix.

So when looking at the products and hardware needed to scale up in the scale-up phase, do you think you have the right optimal portfolio serving that market? And maybe if you could talk about the new product launches? I know it's a little, still a bit early, but 2020 being an important year here. Are number of those products going to serve that segment? Just help us understand how Repligen can continue to seize or grab growth from the cell and gene therapy expansion that's happening here in the end market?

Tony Hunt -- President and Chief Executive Officer

Yeah. So to maybe clarify on this. We definitely play in both cell and gene therapy are predominantly in viral vector manufacturing. So that's kind of the focus area for us.

In terms of our current product portfolio, I think we actually are very well-positioned. Obviously, for the last five, six years, almost all our conversations at the investor level has always been around monoclonal antibodies and a little bit on vaccines and clearly, over the last year, gene therapy has become an important element for us and a vector for us. So if I look at the products that are coming through this year, probably the CS gamma technology that is the flat sheet cassette gamma radiated that's going to be targeted right at our gene therapy customer base. And obviously, our filtration products, as you can tell from the 60% of gene therapy revenue for us coming from our filtration portfolio.

That anything we do on filtration is going to have an impact and benefit to the gene therapy customers.

Puneet Souda -- SVB Leerink -- Analyst

OK. Thank you.

Operator

And our next question today comes from Tycho Peterson of JP Morgan. Please go ahead.

Julia Qin -- J.P. Morgan -- Analyst

Hey, good morning. This is Julia on for Tycho. Thanks for taking my question. So maybe, Tony, just to start off, regarding the seasonality of the protein business in 2020.

I know, obviously, you had some heavy pull forward into the first half of the year, last year. So for 2020, should we expect the seasonality to mirror that of 2019? Or do you expect a different pattern given the GE ramp down? Thanks.

Tony Hunt -- President and Chief Executive Officer

Yeah, I would say, in general, on how you would break up the quarters, typically, Q2 is stronger than Q1, Q3 is light, and Q4 is maybe similar to Q1, right? That's the way it's been for the last number of years. I don't expect that that's going to change. The difference is, obviously, that we will be seeing and are seeing GE volume reduction, right? And we're seeing that in Q1, expect to continue to see that through the year. And we still believe that it will be $12 million to $13 million of a headwind by the time the year is done.

Julia Qin -- J.P. Morgan -- Analyst

OK. And then regarding the capacity ramp, could you give us a sense of how quickly will the new OPUS capacity ramp up in 2020? And what should be the expected sort of gross margin cadence as new capacity is added in sales?

Tony Hunt -- President and Chief Executive Officer

Yeah. So on the capacity side, I think the good news for us and for our customers is that you can see it now, right? Our number of columns doubled in terms of output in 2019. So 1,400 comps versus 700. And as we were going through 2019, we knew we needed to move quickly.

And so in Q4, five OPUS suites were brought online. That essentially gives us additional capacity as we move into 2020. Our lead times have come down significantly. We're in a much better position now than we were, say, a little less than a year ago.

I think the big thing for us on margin has really been the shift that we saw in 2019 where customers, in particular, in North America, have started to send chromatography resins to us. And so our OPUS margins definitely improved in 2019. We expect that that's a trend that should continue in 2020. Probably what we ended up in the Q3, Q4 combined were that we saw a real bump up.

I think that's probably the level that we're going to see. And so we're not expecting that the new capacity that we're building out in 2020 will really come online until late Q3 into Q4. So what we're doing in Europe is really end of the year, start-up the additional suites that we're going to build out here in Waltham is really second half of the year. So we're our capacity expansion plans in 2020 are really with an eye on 2021 and 2022, not really on what's needed to make 2020 a success.

Julia Qin -- J.P. Morgan -- Analyst

Got it. That's very helpful. And then lastly, a follow-up on gene therapy. I mean, given there's a significant sort of a gap between supply and demand in this industry, are you actually seeing that translating to increased pricing leverage on your end?

Tony Hunt -- President and Chief Executive Officer

Yeah. Our products, if you look at how we price our products, whether it's in mAbs or gene therapy, it tends to be very much the same. So there's really not a whole lot of pricing leverage that at least we're seeing at this point.

Julia Qin -- J.P. Morgan -- Analyst

Thank you.

Operator

And our next question comes from Paul Knight at Janney Montgomery Scott. Please go ahead.

Paul Knight -- Janney Montgomery Scott LLC -- Analyst

Hey, Jon, I didn't catch that capex number for 2020.

Jon Snodgres -- Chief Financial Officer

$20 million to $22 million.

Paul Knight -- Janney Montgomery Scott LLC -- Analyst

OK. And then Tony --

Jon Snodgres -- Chief Financial Officer

Go ahead. Sorry.

Paul Knight -- Janney Montgomery Scott LLC -- Analyst

Sorry. Go ahead, Jon.

Jon Snodgres -- Chief Financial Officer

Oh no, I say it's really year two of our capacity expansion program. So we expect the higher capex to go through 2020. And then return back down to more normal levels in 2021.

Paul Knight -- Janney Montgomery Scott LLC -- Analyst

And then Tony, regarding OPUS 80 in the commercial market opening up, does that make your predictive analytics easier? Is it a larger order? Is it a chunkier standby order? How does OPUS 80 help your predictability?

Tony Hunt -- President and Chief Executive Officer

Yeah. So OPUS 80 has tracked very similarly to the OPUS 60 product. And the first year you launch, you get a handful of customers that jump in and say, yeah, I need the larger column. So last year was actually a significant bump up.

And what OPUS 80 has done for us has really opened up Phase 3 and some commercial opportunities. So while the revenue for an OPUS 80 column is definitely more than what you would get for an OPUS 45 or 60, the repeatability of that order is not something that you would expect to see year in, year out because customers are running these columns now for a large number of cycles. So think about our OPUS 80 columns is really replacing the last columns that would be used in Phase 3 or commercial processes. So the expectation is that they'll behave and last just like the normal length of time, you would expect to see it lasting.

So great to be in. I think I've said this a few times over 2019, I think having OPUS 80 in our portfolio has changed the way people think about prepacked columns because now they know they can go, at least for some processes, all the way through to Phase 3 and into commercial.

Paul Knight -- Janney Montgomery Scott LLC -- Analyst

OK. And then lastly, the Purolite relationship is that factory getting busy in England for Purolite. Can you tell?

Tony Hunt -- President and Chief Executive Officer

Yeah, I think it's still early days in terms of the impact of their protein A resins. I don't have the insight in terms of how busy the factory is. I will say that the activity in the field in terms of evaluations using the NGL-Impact A ligand has been really strong. And I think the feedback from customers has been really good, and we expect that we'll see really good growth in NGL ligand revenue in 2020 versus 2019, but it's kind of a long process.

It doesn't happen overnight, but we expect that this is a ligand that's going to be in the market and combined with the Purolite resin is a resin that's going to be in the market for the foreseeable future.

Paul Knight -- Janney Montgomery Scott LLC -- Analyst

OK. Thank you.

Operator

Our next question comes from John Kreger at William Blair. Please go ahead.

John Kreger -- William Blair and Company -- Analyst

Hi, thanks very much. Tony, given all the expansion in the pipeline for gene and cell therapy, has your thoughts changed at all on overall bioprocessing market growth? Are you still viewing that kind of high single digits?

Tony Hunt -- President and Chief Executive Officer

Yeah, I still think we view it in any given year is anywhere between 8% and 12%, right? And it just depends on the year, whether it's a 10%, 12% year or an 8% year. So I think it's probably added 1 to 2 points on to the overall market. That's kind of our assessment.

John Kreger -- William Blair and Company -- Analyst

Great. Thank you. And maybe to clarify the way you guys are thinking about China. Are you assuming any hit and factoring that into your guidance for the full year? Are you really just sort of assuming maybe a shift from Q1 into Q2 or Q3?

Tony Hunt -- President and Chief Executive Officer

Yeah. It hasn't changed our guidance for the year. But I think everybody is in the same sort of place right now, which is no one really knows how long this is going to last. So I think when we get to the May earnings call, I think people will have a much better idea of what the impact is going to be in the first half.

I think for us, we clearly see it as a shift. We've seen no orders getting canceled. It's more around companies that are not up and running at full speed versus where they were in Q4. And so it's that potential delay or shift from Q1 to Q2 that I think will happen for us.

And depending on how basically what happens over the next few months, we'll probably tell a little bit more of what's going to happen first half of this year versus second half of this year.

John Kreger -- William Blair and Company -- Analyst

OK, great. And then one final one. We hear that yields for gene therapy production are way below where monoclonal production is these days. Assuming you agree with that view, do you have a role to play there when you sit down with clients, do you have products that you could plug in that will allow improvements on that front?

Tony Hunt -- President and Chief Executive Officer

Yeah, when you talk to any customer, especially when they're looking at optimizing processes, yield and purity are the top two parameters that people are looking at. It's probably a little unfair to say gene therapy yields are really poor versus mAbs. mAbs have been around since the 1990s, it's gone through 30 years of optimization. It's a really well-understood manufacturing process.

So the fact that the gene therapy manufacturing clients need improved yields is really no surprise, but my expectation is with the technologies that are out there, technologies that we, at Repligen, have. They are the things that we can work on. And you will see yield improvement happening in 2020 and then over the next few years. And if you went out 20 years from now, I'm sure gene therapy yields will be just as predictable as mAb yields are today.

John Kreger -- William Blair and Company -- Analyst

Very helpful. Thank you.

Operator

Our next question comes from Matt Hewitt at Craig-Hallum Capital Group. Please go ahead.

Matt Hewitt -- Craig-Hallum Capital Group -- Analyst

Good morning. Most of my questions have been answered, but I do have one follow-up on gross margins. I think, Tony, you were talking a little bit about how in North America, you've got the customers now sending the resins directly to you. I'm just wondering, as you get the expansion completed in Europe? Will there be an opportunity to do something similar there? And what could that mean to gross margins, maybe not necessarily this year, but as we look at 2021?

Tony Hunt -- President and Chief Executive Officer

Yeah. I mean, that's exactly what I think will happen is that once we build out in Europe for OPUS, it'll be much easier for customers to either ship or transport resins. We're doing it today, but logistically, it's simply a little bit more challenging versus if you have in-country manufacturer, in-manufacturing or in-region manufacturing. So that will definitely improve margins.

I think that contrary to that is, of course, we're dealing with the lost volume that's coming from GE. So that has some margin depression. So at least in 2020, the impact from GE is probably more than offsetting any goodness that's coming through on something like OPUS.

Matt Hewitt -- Craig-Hallum Capital Group -- Analyst

Understood. Thank you.

Operator

And our next question comes from Raghuram Selvaraju of H.C. Wainwright. Please go ahead.

Edward Marks -- H.C. Wainwright -- Analyst

Good morning. This is Edward Marks on for Ram. Most of our questions have been answered as well. But just one follow-up.

Do you still expect to reach your long-term revenue objectives based on this sort of organic growth that you've seen in 2019? And then based on your guidance for 2020?

Tony Hunt -- President and Chief Executive Officer

Yeah. I mean, our long-term growth, our revenue projections are definitely based on being in that 10% to 15% organic growth, but also supplementing it with M&A. So for us to get to where we believe we need to be is going to require additional M&A over the next few years. We also believe that the products that we're developing, and especially the products that we're launching here in 2020, will allow us to grow at the higher end of our 10% to 15% long-term organic growth range.

And we're not as reliant on M&A as maybe we were in 2014, 2015. But just to remind, when we were in 2014, we were saying $50 million to $200 million to $250 million by 2020. We're ahead of that pace. And our expectation is that we're going to continue to execute on this blueprint up.

Great products in the marketplace, very focused on technology innovation, getting new products out and then doing select M&As as we go through the next few years.

Edward Marks -- H.C. Wainwright -- Analyst

Excellent. Thank you.

Operator

And our next question today comes from Jacob Johnson of Stephens. Please go ahead.

Jacob Johnson -- Stephens Inc. -- Analyst

Hey, thanks. Clearly, a lot of growth coming in cell and gene therapy, just on capacity. Are the current investments you're making at OPUS and in filtration enough to handle kind of what you're seeing as you look out over the next couple of years? Or should we expect additional investments here in the near future?

Tony Hunt -- President and Chief Executive Officer

No, I think we took a real step back and looked at what we needed to do back in Q2 last year, and we put a plan in place that goes out over five years. A lot of the capacity expansion that's happening this year is really geared with a three- to five-year horizon. So we think we've got the right plan, obviously. It's based on where we think the market is going to grow and which product lines they're going to grow and what pace they're going to grow at.

But in general, I think we feel like the capacity expansion we're doing right now will keep us well ahead of demand.

Jacob Johnson -- Stephens Inc. -- Analyst

Got it. And then just one more. In proteins, how large is your growth factor business today? And how should we think about the growth in that business within proteins this year?

Tony Hunt -- President and Chief Executive Officer

Yeah, it's been traditionally about a third of our proteins business, and it hasn't really changed that much. And we expect high single-digit to low double-digit growth for that business in the foreseeable future. Kind of matching up, Jacob, more with market growth.

Jacob Johnson -- Stephens Inc. -- Analyst

Got it. Thanks, Tony.

Operator

And our next question today comes from Joe Munda of First Analysis. Please go ahead.

Joe Munda -- First Analysis -- Analyst

Good morning, Tony. Real quick, a lot of questions answered here. But one area of focus I wanted to touch on was gene therapy. You talked about new customers coming on, 50 significant customers where it stands today.

First, can you define what is a significant customer, how big? And then can you talk a little bit about the growth, perhaps new versus existing? If you can give us some color there?

Tony Hunt -- President and Chief Executive Officer

Yeah. So in general, Joe, when we look at customers, our significant customers are the ones who are scaling, that are buying either one product line at a fairly significant amount or they have multiple products in our portfolio. We haven't given out exactly what that revenue is. But it's definitely meaningful and significant for Repligen.

Obviously, when you look at our total revenue last year, 15% of revenue puts us at a little over $40 million. So you get a sense of what those 50 significant customers are contributing toward that $40 million. So we're excited about it. We think we have a really good base of customers in gene therapy.

We're working with the right folks. We also believe that when we look at the landscape, we're about 20% penetrated in the market. So it also tells you a little bit about what the potential is in the future as more and more gene therapy companies start to move from preclinical to Phase 1 to Phase 2. So we're in a good position.

We've got good products, 20% penetrated, got over $40 million in sales last year coming from gene therapy customers and the right sort of mix of CDMOs and gene therapy developers.

Joe Munda -- First Analysis -- Analyst

OK. And that's helpful. And then in China, I know a couple of questions have been touching on it. But I'm curious, the type of business that you're doing in China, is it all products across the board? Or is there a particular focus area, a particular business line that could be potentially impacted? Any clarity there would be great.

Tony Hunt -- President and Chief Executive Officer

So we sell all our products. There isn't one in our portfolio that we don't sell into China. I think it's pretty clear. China is very similar to all of Asia, where our filtration portfolio has significantly more revenue than any of our other businesses.

That said, I think our analytics business and C Tech is doing very well over there and continuing to bring customers on board. We've been pretty open that our prepacked comp business, while we have good business in China and Asia, that's probably been a little harder to get the traction that we've seen in North America and Europe and in Asia with the prepacked comp business. So it's mainly a filtration portfolio exposure.

Joe Munda -- First Analysis -- Analyst

And then my last question. Though you did talk about the long-term goal, and obviously, M&A is going to play a role there. I mean, to the degree you can talk a bout it, but the focus areas, particularly in M&A, know analytics has been a nice driver for you, especially this year. I mean, can you talk a little bit about assets in the space, availability of those assets? And just the multiples you're seeing as far as what it takes to potentially acquire assets in this space?

Tony Hunt -- President and Chief Executive Officer

Yeah. So 2020 is not much different than 2019 in terms of what assets are out there. I think anyone who plays in bioprocessing knows who the players are. It's all about forming relationships and going after the targets that we believe are the right targets for Repligen.

So there's no one area of focus for us. We're clearly just started in analytics. So that's something over time that we will definitely build out. But obviously, we've not stopped looking in the filtration chromatography space.

So all three areas for us are important. In terms of multiples, it just depends, right? So for small companies that are low in revenue, then it's probably -- depending on the type of technology, if you've got technology innovation, then you're paying a high multiple. If it's a more of a me-too type product line, then the multiples are going to be much lower. So in general, the multiples have been in that six to 10x range for a good company with good margins and scaling.

So our expectation is that for the types of companies we're looking at, it's going to be in that range, six to 10x revenue.

Joe Munda -- First Analysis -- Analyst

OK. Thank you.

Operator

And ladies and gentlemen, this concludes the question-and-answer session. I'd like to turn the conference back over to the management team for any final remarks.

Tony Hunt -- President and Chief Executive Officer

Great. Just like to thank everybody for joining us today. Look forward to catching up with everybody in May, and we'll stop here. Thank you.

Operator

[Operator signoff]

Duration: 58 minutes

Call participants:

Sondra Newman -- Global Head of Investor Relations

Tony Hunt -- President and Chief Executive Officer

Jon Snodgres -- Chief Financial Officer

Dan Arias -- Stifel Financial Corp. -- Analyst

Puneet Souda -- SVB Leerink -- Analyst

Julia Qin -- J.P. Morgan -- Analyst

Paul Knight -- Janney Montgomery Scott LLC -- Analyst

John Kreger -- William Blair and Company -- Analyst

Matt Hewitt -- Craig-Hallum Capital Group -- Analyst

Edward Marks -- H.C. Wainwright -- Analyst

Jacob Johnson -- Stephens Inc. -- Analyst

Joe Munda -- First Analysis -- Analyst

More RGEN analysis

All earnings call transcripts